{"id":"W2955217622","doi":"10.1016/j.antiviral.2019.104543","title":"Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1","year":2019,"lang":"en","type":"article","venue":"Antiviral Research","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; Vancouver Infectious Diseases Centre; Canada Research Chairs; McGill University; Maple Leaf Medical Clinic","funders":"Janssen Pharmaceuticals; Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; Arthur Foundation; Johnson and Johnson; Gilead Sciences; Merck; Yale University","keywords":"Darunavir; Emtricitabine; Tenofovir alafenamide; Medicine; Internal medicine; Adverse effect; Cobicistat; Gastroenterology; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002605218,0.001750973,0.001702674,0.0003632391,0.000414128,0.001117436,0.001022208,0.001865844,0.006398886],"category_scores_gemma":[0.002164041,0.0006734141,0.001674701,0.0002454462,0.001070497,0.001370579,0.0003891117,0.003812607,0.001404598],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007324751,"about_ca_system_score_gemma":0.0006953825,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003920892,"about_ca_topic_score_gemma":0.0009925634,"domain_scores_codex":[0.9990325,0.0005322457,0.00005342092,0.0001778717,0.00006665114,0.0001372785],"domain_scores_gemma":[0.9989643,0.0002366126,0.0002879774,0.0001268988,0.00006863371,0.0003156118],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9669318,0.01329146,0.001076646,0.0002120942,0.0004412791,0.00005233155,0.00006934167,0.0005548659,0.00388334,0.00008430832,0.000861601,0.01254099],"study_design_scores_gemma":[0.8424467,0.1491612,0.005030203,0.00003083565,0.0002592237,0.00006588103,0.00002893255,0.0005886513,0.001373038,0.0002108495,0.0007797545,0.0000248257],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909168,0.001014587,0.0004833397,0.0003460066,0.0001586969,0.002383727,0.002085906,0.0001039155,0.002507124],"genre_scores_gemma":[0.9903479,0.0004957248,0.001014927,0.0006170683,0.0001372842,0.002276354,0.001405016,0.00002789764,0.003677723],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006398886,"threshold_uncertainty_score":0.02140641,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03428119433678359,"score_gpt":0.3278131052699593,"score_spread":0.2935319109331758,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}